Final results of a phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

被引：5
|
作者：
Richardson, Paul G. [1 ]
Mitsiades, Constantine S. [1 ]
Colson, Kathleen [1 ]
Reilly, Eileen [2 ]
McBride, Laura [2 ]
Chiao, Judy
Sun, Linda
Ricker, Justin L. [3 ]
Rizvi, Syed [3 ]
Oerth, Carol [3 ]
Atkins, Barbara [3 ]
Fearen, Ivy
Anderson, Kenneth C. [1 ]
Siegel, David S. [2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Hackensack Univ, Med Ctr, Ctr Canc, Hackensack, NJ USA
[3] Merck Res Labs, Upper Gwynedd, PA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.1179.1179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1179
引用
收藏
页码：357A / 357A
页数：1
相关论文
共 50 条
  • [1] Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
    Richardson, Paul
    Mitsiades, Constantine
    Colson, Kathleen
    Reilly, Eileen
    Mcbride, Laura
    Chiao, Judy
    Sun, Linda
    Ricker, Justin
    Rizvi, Syed
    Oerth, Carol
    Atkins, Barbara
    Fearen, Ivy
    Anderson, Kenneth
    Siegel, David
    LEUKEMIA & LYMPHOMA, 2008, 49 (03) : 502 - 507
  • [2] Phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma
    Weber, Donna M.
    Jagannath, Sundar
    Mazumder, Amitabha
    Sobecks, Ronald
    Schiller, Gary J.
    Gavino, Maria
    Sumbler, Chantelle
    McFadden, Carrie
    Chen, Cong
    Ricker, Justin L.
    Rizvi, Syed
    Oerth, Carol
    Brownell, Patricia
    Husein, Mohamad A.
    BLOOD, 2007, 110 (11) : 355A - 355A
  • [3] Phase I trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with solid tumors
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Yamada, Kazuhiko
    Yamada, Yasuhide
    Koizumi, Fumiaki
    Shimoyama, Tatsu
    Nishio, Kazuto
    Otsuki, Tetsuya
    Frankel, Stanley R.
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S459 - S459
  • [4] Clinical responses to oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) are associated with specific gene expression signatures in patients with advanced leukemias: Results of a phase I trial.
    Loboda, Andrey
    Fantin, Valeria R.
    Bueso-Ramos, Carlos E.
    Randolph, Sophia
    Hardwick, James S.
    Ricker, Justin L.
    Richon, Victoria M.
    Issa, Jean-Pierre
    Kantarjian, Hagop M.
    Frankel, Stanley R.
    Garcia-Manero, Guillermo
    BLOOD, 2006, 108 (11) : 657A - 657A
  • [5] Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL): Final results of a phase II trial
    Crump, M.
    Coiffier, B.
    Jacobsen, E. D.
    Sun, L.
    Ricker, J. L.
    Xie, H.
    Frankel, S. R.
    Randolph, S. S.
    Cheson, B. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Phase I trial of suberoylanilide hydroxamic acid (SAHA) plus bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts).
    Badros, Ashraf
    Philip, S.
    Niesvizky, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J.
    Burger, A.
    Grant, S.
    Baer, M. K.
    Egorin, M. J.
    BLOOD, 2007, 110 (11) : 354A - 354A
  • [7] A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with gastrointestinal (GI) cancer
    Chin, K.
    Hatake, K.
    Hamaguchi, T.
    Shirao, K.
    Doi, T.
    Noguchi, K.
    Garcia-Vargas, J. E.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed/refractory multiple myeloma
    Richardson, P
    Schlossman, RL
    Mitsiades, CS
    Munshi, NC
    Colson, K
    Doss, D
    McKenney, M
    Hande, K
    Gorelik, S
    Lunde, L
    Stepanek, A
    Freeman, A
    Dinand, K
    Hayes, S
    Michelle, R
    Doucet, K
    Warren, D
    Mitsiades, N
    Richon, VM
    Chiao, J
    Anderson, KC
    BLOOD, 2004, 104 (11) : 420A - 420A
  • [9] A phase I and pharmacokinetic/pharmacodynamic study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with solid tumor
    Fujiwara, Y.
    Yamamoto, N.
    Yamada, K.
    Yamada, Y.
    Shimoyama, T.
    Koizmi, F.
    Nishio, K.
    Otsuki, T.
    Frankel, S. R.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase I study of oral suberoylanilide hydroxamic acid (SAHA) in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS).
    Garcia-Manero, G
    Canalli, AA
    Wierda, W
    Cortes, J
    O'Brien, S
    Cupo, A
    Secrist, JP
    Davis, J
    Faderl, S
    Giles, F
    Chiao, JH
    Richon, V
    Issa, JP
    Kantarjian, H
    BLOOD, 2003, 102 (11) : 254B - 254B
12345